title: Medical management of glaucoma: principles and practice.
abstract: Glaucoma care is more an art than science. The introduction of several new classes of glaucoma medications and the completion of many large randomized clinical trials have not changed this fact. While we now have better choices when initiating glaucoma therapy relative to our predecessors, the principles of glaucoma therapy have not changed much during this period. Debates continue regarding the utility of concepts such as "the monocular therapeutic trial," "target intraocular pressure (IOP)," and "maximal medical therapy." Our tools for detecting and following glaucomatous disease have improved but are not precise enough for us to prospectively predict which patients will do better or worse than others. Much attention has been given to disease stage, rate of progression, and compliance with medications but regular patient follow-up, an area that has received little attention, may be among the most important predictors of patient outcomes.
authors.affiliation: Glaucoma Service, Stanford University School of Medicine, 900 Blake Wilbur Drive, Palo Alto, CA 94305, USA. Kuldev.Singh@Stanford.edu
authors.forename: Kuldev
authors.initials: K
authors.lastname: Singh
authors.forename: Anurag
authors.initials: A
authors.lastname: Shrivastava
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D018450:Disease Progression; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006040:Goals; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D010277:Parasympathomimetics / Q000627:therapeutic use; D011453:Prostaglandins / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002257:Carbonic Anhydrase Inhibitors; D010277:Parasympathomimetics; D011453:Prostaglandins